Loading...
•
Jun 30, 2025
Eli Lilly Q2 2025 Earnings Report
Eli Lilly delivered strong Q2 2025 performance driven by product volume growth and margin expansion.
Key Takeaways
Lilly reported 38% year-over-year revenue growth to $15.56 billion and a 92% increase in EPS to $6.29, driven by robust sales of Zepbound and Mounjaro, expanded margins, and raised full-year guidance.
Worldwide revenue grew 38% to $15.56 billion
Volume increased 42%, offsetting a 6% price decline
Gross margin expanded to 84.3% of revenue
Full-year revenue and EPS guidance were raised
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Lilly raised its full-year 2025 financial outlook across revenue, EPS, and margins based on strong first half performance.
Positive Outlook
- Full-year revenue guidance increased to $60.0–62.0 billion
- Reported EPS guidance raised to $20.85–22.10
- Non-GAAP EPS guidance raised to $21.75–23.00
- Reported performance margin guidance increased to 42.0–43.5%
- Non-GAAP performance margin guidance increased to 43.0–44.5%
Challenges Ahead
- Reported other income/(expense) expected at a $750–650 million expense
- Non-GAAP other income/(expense) expected at a $700–600 million expense
- Reported effective tax rate guidance increased to approx. 19%
- Guidance excludes acquired IPR&D charges after Q2 2025
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...